On November 22, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York (Press release, Infinity Pharmaceuticals, NOV 22, 2022, View Source [SID1234624338]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29, 2022
Time: 4:00 p.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
View Source;tp_key=e9a7246381

A replay of the presentation will be available in the Investors/Media section of Infinity’s website at www.infi.com for 90 days following the event.